Advances in Alport syndrome diagnosis using next-generation sequencing

Area of Science:

• Genetics
• Molecular Biology
• Nephrology

Background:

• Alport syndrome (ATS) is a hereditary kidney disease often linked to hearing and vision impairments.
• Mutations in COL4A5, COL4A4, and COL4A3 genes cause X-linked, autosomal recessive, or autosomal dominant forms of ATS.
• Conventional mutation screening methods are slow and expensive due to the large size of these genes.

Purpose of the Study:

• To develop and validate a next-generation sequencing (NGS) protocol for simultaneous mutation detection in COL4A3, COL4A4, and COL4A5.
• To improve the diagnostic efficiency and reduce the time and cost associated with Alport syndrome diagnosis.

Main Methods:

• Designed and implemented an NGS protocol using selective amplification coupled with the 454 Roche DNA sequencing platform.
• Applied the NGS protocol to screen for mutations in the three primary genes associated with Alport syndrome.

Main Results:

• Successfully identified the second mutation in two Alport syndrome patients (p.Ser1147Phe in COL4A3 and p.Arg1682Trp in COL4A4).
• Enabled re-evaluation and confirmed the diagnosis of ATS in a third patient.
• Demonstrated the effectiveness of NGS for diagnosing Mendelian disorders with locus heterogeneity.

Conclusions:

• NGS provides a powerful tool for rapid and comprehensive mutation screening in Alport syndrome.
• This approach overcomes the limitations of conventional methods, accelerating diagnosis and potentially improving patient management.
• The study highlights the utility of NGS in diagnosing complex genetic disorders with multiple causative genes.